Note 3 - Certain Uncertainties	9 Months Ended
Sep. 30, 2020
Notes to Financial Statements
Certain Uncertainties [Text Block]	Certain Uncertainties The Company's consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all. The Company is monitoring the potential impact of the novel coronavirus (COVID- 19 ), if any, on the carrying value of certain assets. To date, as a direct result of COVID- 19, the HRL operations were temporarily shut-down on March 24, 2020. HRL's operations recommenced on May 25, 2020 and the temporary shut-down had a negative impact on HRL's revenue and our ability to produce Xprecia Stride TM strips during this period. HRL collects blood samples from donors located at hospital clinics and community blood collection sites. These blood samples are used for calibration and testing services. Xprecia Stride TM strips produced by UBI are required to be calibrated so that all products agree with an international standard. The calibration services are performed by HRL. The extent to which these events may impact the Company's business moving forward will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company will continue to assess the financial impact.

Certain Uncertainties

The Company's consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next

twelve

months. However, in the event our financing needs for the foreseeable future are

not

able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is

assurance that funding would be available at acceptable terms, if at all.

The Company is monitoring the potential impact of the novel coronavirus (COVID-

), if any, on the carrying value of certain assets. To date, as a direct result of COVID-

19,

the HRL operations were temporarily shut-down on

March 24, 2020.

HRL's operations recommenced on

May 25, 2020

and the temporary shut-down had a negative impact on HRL's revenue and our ability to produce Xprecia Stride

strips during this period. HRL collects blood samples from donors located at hospital clinics and community blood collection sites. These blood samples are used for calibration and testing services. Xprecia Stride

strips produced by UBI are required to be calibrated so that all products agree with an international standard. The calibration services are performed by HRL. The extent to which these events

may

impact the Company's business moving forward will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company will continue to assess the financial impact.